Results 231 to 240 of about 375,096 (307)
This study reveals that the Fgl2‐FcγRIIB signaling axis is a key mechanism by which MDSCs mediate tumor immune evasion. Tumor‐derived exosomes systemically activate MDSCs via this pathway, positioning this axis as a promising broad‐spectrum target for cancer immunotherapy.
Fenglin Lin +12 more
wiley +1 more source
C-X-C chemokine receptor type 4 (CXCR4) antagonism in precision oncology: Clinical applications and future directions. [PDF]
Rajendran A +3 more
europepmc +1 more source
ABSTRACT Advancements in tissue engineering have revolutionized therapeutic paradigms for diabetic tissue defects; however, the lack of applicable scaffold containing various bioactive substance aggregates remained a critical bottleneck hindering satisfactory repair effect.
Tao Wang +8 more
wiley +1 more source
C-X-C chemokine receptor family genes in osteosarcoma: expression profiles, regulatory networks, and functional impact on tumor progression. [PDF]
Dong S +6 more
europepmc +1 more source
Tumor dsDNA released by cryoablation is taken up by macrophages, activating the cGAS‐STING signaling pathway. This leads to an expansion of the CXCL10+ macrophage pool and increased secretion of CXCL10, which in turn recruits CXCR3+ T cells from draining lymph nodes into the tumor microenvironment to exert anti‐tumor effects.
Xinxin Zhi +17 more
wiley +1 more source
Transcriptomic Analysis Reveals C-C Motif Chemokine Receptor 1 as a Critical Pathogenic Hub Linking Sjögren's Syndrome and Periodontitis. [PDF]
Lin Y +6 more
europepmc +1 more source
Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun +15 more
wiley +1 more source
Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer. [PDF]
McDonald HG +18 more
europepmc +1 more source
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang +8 more
wiley +1 more source
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source

